Viewing Study NCT06682169


Ignite Creation Date: 2025-12-24 @ 10:46 PM
Ignite Modification Date: 2025-12-25 @ 8:16 PM
Study NCT ID: NCT06682169
Status: RECRUITING
Last Update Posted: 2025-12-08
First Post: 2024-11-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module